CenterBook Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

CenterBook Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$555K	Sell	9,243 -24,672	-73%	-$1.55M	0.03%	618
2026 Q2	$1.94M	Buy	+33,915	New	+$1.86M	0.1%	239
2026 Q1	–	Sell	-35,718	Closed	-$2.12M	–	659
2025 Q4	$2.12M	Buy	+35,718	New	+$1.94M	0.1%	257
2023 Q4	–	Sell	-10,534	Closed	-$932K	–	397
2023 Q3	$932K	Sell	10,534 -2,776	-21%	-$247K	0.12%	257
2023 Q2	$1.15M	Buy	13,310 +4,365	+49%	+$411K	0.14%	220
2023 Q1	$870K	Buy	8,945 +507	+6%	+$52.6K	0.12%	253
2022 Q4	$873K	Sell	8,438 -2,079	-20%	-$195K	0.14%	217
2022 Q3	$892K	Buy	10,517 +1,895	+22%	+$169K	0.17%	202
2022 Q2	$715K	Buy	8,622 +1,480	+21%	+$118K	0.15%	229
2022 Q1	$551K	Sell	7,142 -2,567	-26%	-$215K	0.2%	187
2021 Q4	$858K	Buy	+9,709	New	+$801K	0.5%	57

Other funds holding BMRN

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

CenterBook Partners's BMRN Position: Q3 2026 in Review

CenterBook Partners reduced its BioMarin Pharmaceuticals (BMRN) stake by 73% in Q3 2026, selling an estimated $1.55M and leaving 9,243 shares worth $555K. The position accounts for 0.03% of the portfolio, ranked #618.

CenterBook Partners first reported a position in BMRN in Q4 2021 and has held it in 11 quarters since. The position peaked at $2.12M in Q4 2025. 434 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

CenterBook Partners held 9,243 shares of BioMarin Pharmaceuticals worth $555K as of Q3 2026.
CenterBook Partners sold 24,672 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $1.55M.
BioMarin Pharmaceuticals made up 0.03% of CenterBook Partners's portfolio in Q3 2026, its #618 holding.
CenterBook Partners first reported a position in BioMarin Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
CenterBook Partners's BioMarin Pharmaceuticals position peaked at $2.12M in Q4 2025.
434 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on CenterBook Partners's 13F filing for Q3 2026, filed 2 Nov 2026.